Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583476 | 0.82 | GRIN2B (0.34) | — | |
| SCHEMBL6399212 | 0.80 | AKR1B1 (0.41) | KDM4EALDH1A1GAAMAPTCA2 | |
| SCHEMBL4818565 | 0.78 | KDM4E (0.36) | KDM4EALDH1A1ALOX5GAAMAPT | |
| SCHEMBL4893807 | 0.76 | ESR2 (0.39) | — | |
| SCHEMBL18998250 | 0.73 | ADRA2A (0.40) | KDM4EALDH1A1GAAMAPTBACE1 | |
| SCHEMBL3990720 | 0.73 | APP (0.40) | ALDH1A1BACE1 | |
| SCHEMBL12465068 | 0.72 | NPC1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL8853672 | 0.71 | ALDH1A1 (0.48) | KDM4EALDH1A1ALOX5GAAMAPT | |
| SCHEMBL6687949 | 0.70 | SIGMAR1 (0.40) | KDM4EALDH1A1BACE1 | |
| SCHEMBL7998432 | 0.70 | ALDH1A1 (0.47) | KDM4EALDH1A1ALOX5GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | KDM4E 879/4885ALDH1A1 788/4885ALOX5 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.